Editor's note: We invite readers to submit comments on the JUPITERtrial in a new interactive feature, Clinical Directions –The JUPITER Trial: Will You Change Your Practice? Commentingcloses November 26, 2008.
The aphorism "prevention is better than cure" makes perfectsense when applied to healthy habits such as following a sensiblediet, maintaining an ideal body weight, exercising regularly,and not smoking. But increasingly, prevention of cardiovasculardisease includes drug therapy, particularly statins to lowercholesterol levels. Statins were first tested in subjects athigh risk for coronary events, and the limits of treatment havesubsequently been expanded to include persons at progressivelylower risk.1 The results of the Justification for the Use ofStatins in Primary Prevention: an Intervention Trial EvaluatingRosuvastatin (JUPITER; ClinicalTrials.gov number, NCT00239681
[ClinicalTrials.gov]
),reported by Ridker . . . [Full Text of this Article]
Source Information
This article (10.1056/NEJMe0808320) was published at www.nejm.org on November 9, 2008.
From the Stanford University School of Medicine, Stanford, CA.
This article has been cited by other articles:
Buckley, D. I., Fu, R., Freeman, M., Rogers, K., Helfand, M.
(2009). C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force. ANN INTERN MED
151: 483-495
[Abstract][Full Text]
Kones, R.
(2009). The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Ther Adv Cardiovasc Dis
3: 309-315
[Abstract]
Elliott, P., Chambers, J. C., Zhang, W., Clarke, R., Hopewell, J. C., Peden, J. F., Erdmann, J., Braund, P., Engert, J. C., Bennett, D., Coin, L., Ashby, D., Tzoulaki, I., Brown, I. J., Mt-Isa, S., McCarthy, M. I., Peltonen, L., Freimer, N. B., Farrall, M., Ruokonen, A., Hamsten, A., Lim, N., Froguel, P., Waterworth, D. M., Vollenweider, P., Waeber, G., Jarvelin, M.-R., Mooser, V., Scott, J., Hall, A. S., Schunkert, H., Anand, S. S., Collins, R., Samani, N. J., Watkins, H., Kooner, J. S.
(2009). Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease. JAMA
302: 37-48
[Abstract][Full Text]
Vaccarino, V., Bremner, J. D., Kelley, M. E.
(2009). JUPITER: A Few Words of Caution. Circ Cardiovasc Qual Outcomes
2: 286-288
[Full Text]
Glynn, R. J., MacFadyen, J. G., Ridker, P. M
(2009). Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study. Clin. Chem.
55: 305-312
[Abstract][Full Text]
Vasan, R. S
(2009). Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness. Int J Epidemiol
38: 231-234
[Full Text]
SHISHEHBOR, M. H., HAZEN, S. L.
(2009). JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. Cleveland Clinic Journal of Medicine
76: 37-44
[Abstract][Full Text]
(2008). More Data on Statins in Primary Prevention -- The JUPITER Study. JWatch General
2008: 1-1
[Full Text]
Previous
